1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002 [ J ]. CA Cancer J Clin,2005,55:74 - 108.
2Pao W, Miller V, Zakowski M,et al. EGF receptor gene mutations are common in lung cancers from'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib [ J ]. Proc Natl Acad Sci USA 2004,101 : 13306 - 13311.
4Choong NW, Dietrich S, Seiwert TY,et al. Gefitinib response of erlotinib - refractmy lung cancer involving meninges - role of EGFR mutation[J]. Nat Clin Pract Oncol,2006,3 : 50 -57.
5Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small - cell lung cancer to gefitinib [ J ]. N Engl J Med, 2004,350 ( 21 ) : 2129 - 2139.
6Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non -snarll -cell lung cancer ( IDEAL - 1 )[M ]. Proc ASCO,2002,21:298a ( Abstract 1188).
7Kris M, Natale RB, Her t RS, et al. A phase II trial of ZD1839 ( Iressa) in advanced non - small cell lung cancer ( NSCLC ) patients who had failed platinum - and docetaxel - based regime ( IDEAL - 2 ) [ M]. Proc ASCO,2002,21:292a (Abstract 1164).
8Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR[J]. Nat Genet,2005,37(12) : 1315 -1316.
9Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J]. PLoS Med,2005,2 :e73.
10Soh J, Toyooka S, Ichihara S, et al. EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinlb [ J ]. Lung Cancer,2007,56(3 ) :445 -448.
2Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors [J]. J Natl Cancer Inst, 2000,92(3) :205-216.
3Kosmidis P. Chemotherapy in NSCLC: histrocial review [J].Lung Cancer, 2002,38(Suppl 3):S19-S22.
4Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy [J]. J Clin Oncol, 2000,18(10): 2095-2103.
5Fossella DV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy regimens [J]. J Clin Oncol,2000,18(12) :2354-2362.
6Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. J Clin Oncol, 2003,21 (12): 2237-2246.
7Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer [J]. JAMA, 2003,290(16) :2149-2158.
8Lynch, T, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying resensiveness of non-small-cell lung cancer to gefitinib [J]. N Engl J Med,2004,350(21 ): 2129-2139.
9Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [J]. Science, 2004,304(5676): 1497-1500.
10Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in nonsmall cell lung cancers related to gefitinib responsiveness in Taiwan [J]. Clin Cancer Res, 2004, 10(24) :8195-8203.
5Pop LA,Puscas E,PiIeczki V,et al.Quality control of Ion Torrent sequencing library[J].Cancer Biomark,2014,14(2):93-101.
6Hassan SM,Vossen RH,Chessa R.Molecular diagnostics of theHBB gene in an Omani cohort using bench-top DNA Ion TorrentPGM technology[J].Blood Cells Mol Dis,2014,28(5):1079-1096.
7Angelidaki I.Analysis of bacterial communities and bacterial patho-gens in a biogas plant by the combination of ethidium monoazide,PCR and Ion Torrent sequencing[J].Water Res,2014,60(1):156-163.
8Tsongalis GJ,Peterson JD,de Abreu FB,et al.Routine use of theIon Torrent AmpliSeq^TM Cancer Hotspot Panel for identification of clinically actionable somatic mutations[J].Clin Chem Lab Med,2014,52(5):707-714.
